PDF herunterladen
CC BY-NC-ND 4.0 · Indian Journal of Neurotrauma 2020; 17(01): 37-41
DOI: 10.1055/s-0040-1713457
Review Article

Mitochondrial Dysfunction in Traumatic Brain Injury: Management Strategies

Carlos-Andrés Bonilla-Mendoza
1   Centro de Investigaciones Biomédicas (CIB), Faculty of Medicine, University of Cartagena, Cartagena, Columbia
,
Ezequiel Garcia-Ballestas
1   Centro de Investigaciones Biomédicas (CIB), Faculty of Medicine, University of Cartagena, Cartagena, Columbia
,
Alfonso Pacheco-Hernandez
2   Fundación Centro Colombiano de Epilepsia y Enfermedades Neurologicas–FIRE, Faculty of Medicine, University of Cartagena, Cartagena, Columbia
,
Luis-Rafael Moscote-Salazar
3   Centro de Investigaciones Biomedicas (CIB), Cartagena Neurotrauma Research Group Research Line, Faculty of Medicine, University of Cartagena, Cartagena, Columbia
,
Ravish R. Keni
4   Department of Neurology, Narayana Medical College and Hospital, Nellore, Andhra Pradesh, India
,
Amit Agrawal
5   Department of Neurosurgery, Narayana Medical College and Hospital, Nellore, Andhra Pradesh, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Today, traumatic brain injuries continue to be studied, increasingly investigating the pathophysiological mechanisms that contribute to the clinical presentation, severity, and possible sequelae, but despite this, the prognosis of these patients is sometimes poor. Mitochondrial dysfunction comprises a series of reactions that contribute to the inflammatory process in these patients that have an impact on the prognosis, since it is one of the pathophysiological mechanisms involved in secondary lesions after a traumatic brain injury; and therefore has opened a field of study in the search of possible biomolecular markers that allow us to establish a prognosis and prediction of mortality.

Keywords

mitochondria - traumatic brain injury - apoptosis


Publikationsverlauf

Artikel online veröffentlicht:
11. August 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Wang WX, Sullivan PG, Springer JE. Mitochondria and microRNA crosstalk in traumatic brain injury. Prog Neuropsychopharmacol Biol Psychiatry 2017; 73: 104-108
    CrossrefPubMedGoogle Scholar
  • 2 Yonutas HM, Vekaria HJ, Sullivan PG. Mitochondrial specific therapeutic targets following brain injury. Brain Res 2016; 1640 (Pt A) 77-93
    CrossrefPubMedGoogle Scholar
  • 3 González-Domínguez R. Medium-chain fatty acids as biomarkers of mitochondrial dysfunction in traumatic brain injury. EBioMedicine 2016; 12: 8-9
    CrossrefPubMedGoogle Scholar
  • 4 Hiebert JB, Shen Q, Thimmesch AR, Pierce JD. Traumatic brain injury and mitochondrial dysfunction. Am J Med Sci 2015; 350 (02) 132-138
    CrossrefPubMedGoogle Scholar
  • 5 Dobrachinski F, da Rosa Gerbatin R, Sartori G. et al. Regulation of mitochondrial function and glutamatergic system are the target of guanosine effect in traumatic brain injury. J Neurotrauma 2017; 34 (07) 1318-1328
    CrossrefPubMedGoogle Scholar
  • 6 Charry JD, Cáceres JF, Salazar AC. et al. Trauma craneoencefálico. Revisión de la literatura. Rev Chil Neurocir. 2017; 43: 177-182
    PubMedGoogle Scholar
  • 7 Grimm A, Eckert A. Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem 2017; 143 (04) 418-431
    CrossrefPubMedGoogle Scholar
  • 8 Saha P, Gupta R, Sen T, Sen N. Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury. Neurobiol Dis 2018; 118: 108-116
    CrossrefPubMedGoogle Scholar
  • 9 Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014; 94 (03) 909-950
    CrossrefPubMedGoogle Scholar
  • 10 Singh IN, Sullivan PG, Deng Y, Mbye LH, Hall ED. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J Cereb Blood Flow Metab 2006; 26 (11) 1407-1418
    CrossrefPubMedGoogle Scholar
  • 11 Hill RL, Singh IN, Wang JA, Hall ED. Time courses of post-injury mitochondrial oxidative damage and respiratory dysfunction and neuronal cytoskeletal degradation in a rat model of focal traumatic brain injury. Neurochem Int 2017; 111: 45-56
    CrossrefPubMedGoogle Scholar
  • 12 Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP. Impaired cerebral mitochondrial function after traumatic brain injury in humans. J Neurosurg 2000; 93 (05) 815-820
    CrossrefPubMedGoogle Scholar
  • 13 Hu C, Huang Y, Li L. Drp1-dependent mitochondrial fission plays critical roles in physiological and pathological progresses in mammals. Int J Mol Sci 2017; 18 (01) 144
    CrossrefPubMedGoogle Scholar
  • 14 Fischer TD, Hylin MJ, Zhao J, Moore AN, Waxham MN, Dash PK. Altered mitochondrial dynamics and TBI pathophysiology. Front Syst Neurosci 2016; 10: 29
    CrossrefPubMedGoogle Scholar
  • 15 Venegoni W, Shen Q, Thimmesch AR, Bell M, Hiebert JB, Pierce JD. The use of antioxidants in the treatment of traumatic brain injury. J Adv Nurs 2017; 73 (06) 1331-1338
    CrossrefPubMedGoogle Scholar
  • 16 Zhu Y, Wang H, Fang J. et al. SS-31 provides neuroprotection by reversing mitochondrial dysfunction after traumatic brain injury. Oxid Med Cell Longev 2018; 2018: 4783602
    PubMedGoogle Scholar
  • 17 Millet A, Bouzat P, Trouve-Buisson T. et al. Erythropoietin and its derivates modulate mitochondrial dysfunction after diffuse traumatic brain injury. J Neurotrauma 2016; 33 (17) 1625-1633
    CrossrefPubMedGoogle Scholar
  • 18 Mohamadpour M, Whitney K, Bergold PJ. The importance of therapeutic time window in the treatment of traumatic brain injury. Front Neurosci 2019; 13: 07
    CrossrefPubMedGoogle Scholar